EUVIMEDEUVIMED entdecken
Editorial

Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology

Amalia M Issa

Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)

DOI: 10.1002/cpdd.70079 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.07.2026. Verfasst von Amalia M Issa. Beteiligte Einrichtung: Editor-in-Chief, Clinical Pharmacology in Drug Development, American College of Clinical Pharmacology, Ashburn, VA, USA. Die Arbeit nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Editor-in-Chief, Clinical Pharmacology in Drug Development, American College of Clinical Pharmacology, Ashburn, VA, USA.

Zitieren

APA

Issa, A. M. (2026). Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70079

Vancouver

Issa AM. Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70079

BibTeX
@article{Issa2026,
  author = {Issa, Amalia M},
  title = {Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cpdd.70079}
}
Kostenlos starten →